Blood amyloid-β oligomerization as a biomarker of Alzheimer's disease: a blinded validation study
YC Youn, BS Lee, GJ Kim, JS Ryu… - Journal of …, 2020 - content.iospress.com
Journal of Alzheimer's Disease, 2020•content.iospress.com
Background: Oligomeric amyloid-ß (Aß) is one of the major contributors to the
pathomechanism of Alzheimer's disease (AD); Aß oligomerization in plasma can be
measured using a Multimer Detection System-Oligomeric Aß (MDS-OAß) after incubation
with spiked synthetic Aß. Objective: We evaluated the clinical sensitivity and specificity of the
MDS-OAß values for prediction of AD. Methods: The MDS-OAß values measured using
inBlood™ OAß test in heparin-treated plasma samples from 52 AD patients in comparison …
pathomechanism of Alzheimer's disease (AD); Aß oligomerization in plasma can be
measured using a Multimer Detection System-Oligomeric Aß (MDS-OAß) after incubation
with spiked synthetic Aß. Objective: We evaluated the clinical sensitivity and specificity of the
MDS-OAß values for prediction of AD. Methods: The MDS-OAß values measured using
inBlood™ OAß test in heparin-treated plasma samples from 52 AD patients in comparison …
Abstract
Background: Oligomeric amyloid-ß (Aß) is one of the major contributors to the pathomechanism of Alzheimer’s disease (AD); Aß oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric Aß (MDS-OAß) after incubation with spiked synthetic Aß.
Objective: We evaluated the clinical sensitivity and specificity of the MDS-OAß values for prediction of AD. Methods: The MDS-OAß values measured using inBlood™ OAß test in heparin-treated plasma samples from 52 AD patients in comparison with 52 community-based subjects with normal cognition (NC). The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required at least 6 months of follow-up from the initial clinical diagnosis in the course of AD.
Results: The MDS-OAß values were 1.43±0.30 ng/ml in AD and 0.45±0.19 (p< 0.001) in NC, respectively. Using a cut-off value of 0.78 ng/ml, the results revealed 100% sensitivity and 92.31% specificity. Conclusion: MDS-OAß to measure plasma Aß oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity.
content.iospress.com
以上显示的是最相近的搜索结果。 查看全部搜索结果